Oral faecal microbiota transplantation in ulcerative colitis - Authors' reply
- PMID: 35278396
- DOI: 10.1016/S2468-1253(22)00045-0
Oral faecal microbiota transplantation in ulcerative colitis - Authors' reply
Conflict of interest statement
CH reports speaker fees, educational support, and travel sponsorship from Janssen, Pfizer, Takeda, Ferring, Sandoz, and AbbVie. SP has served as a consultant for Finch Therapeutics and AbbVie and has received speaker fees and educational support from Ferring, Janssen, Takeda, and Dr Falk Pharma. RWL reports grants, educational support, and speaker fees from Joanna Tiddy through Sydney University, Pfizer Takeda, Ferring, Dr Falk Pharma, and AbbVie; and participation on advisory boards for AbbVie, Aspen, BMS, Celgene, Chiesi, Emerge Health, Ferring, Glutagen, Hospira, Janssen, Novartis, Pfizer, Takeda, and MSD. NOK declares no competing interests.
Comment on
-
Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.Lancet Gastroenterol Hepatol. 2022 Feb;7(2):141-151. doi: 10.1016/S2468-1253(21)00400-3. Epub 2021 Dec 2. Lancet Gastroenterol Hepatol. 2022. PMID: 34863330 Clinical Trial.
-
Oral faecal microbiota transplantation in ulcerative colitis.Lancet Gastroenterol Hepatol. 2022 Apr;7(4):286. doi: 10.1016/S2468-1253(21)00469-6. Lancet Gastroenterol Hepatol. 2022. PMID: 35278395 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
